, a modification that regulates transcription elongation, splicing, and cleavage and polyadenylation 8, 9 . Genome-wide expression studies suggest that depletion of CDK12 abrogates the expression of several HR genes relatively specifically, thereby blunting HR repair 3-7,10,11 . This observation suggests that the mutational status of CDK12 may predict sensitivity to targeted treatments against BRCAness, such as PARP1 inhibitors, and that CDK12 inhibitors may induce sensitization of HR-competent tumours to these treatments 6, 7, 10, 11 . Despite growing clinical interest, the mechanism by which CDK12 regulates HR genes remains unknown. Here we show that CDK12 globally suppresses intronic polyadenylation events in mouse embryonic stem cells, enabling the production of full-length gene products. Many HR genes harbour more intronic polyadenylation sites than other expressed genes, and these sites are particularly sensitive to loss of CDK12. The cumulative effect of these sites accounts for the enhanced sensitivity of HR gene expression to CDK12 loss, and we find that this mechanism is conserved in human tumours that contain lossof-function CDK12 mutations. This work clarifies the function of CDK12 and underscores its potential both as a chemotherapeutic target and as a tumour biomarker.
. We sought to dissect the molecular function of CDK12 by generating Cdk12 genetic knockouts (Cdk12∆) in mES cells that express a complementing, doxycycline (Dox)-inducible Cdk12 transgene under continuous Dox treatment (Extended Data Fig. 1a, b) . Upon withdrawal of Dox, CDK12 was depleted after 24 h and undetectable after 48 h (Fig. 1a, Extended Data Fig. 1c ). Loss of CDK12 yielded a progressive cell viability defect after 72 h of Dox depletion, which was reversible upon CDK12 re-expression (Fig. 1b, Extended Data Fig. 1d) . Notably, the initial 48 h of CDK12 depletion had minimal consequences on viability, providing a window in which to probe CDK12 function.
The cell viability defect observed upon CDK12 loss could be due to decreased proliferation and/or increased cell death. Cell cycle profiling upon CDK12 depletion revealed decreased nucleotide incorporation during S-phase and a shift in the proportion of cells from S-phase to G1, which was reversed upon re-expression of CDK12 (Fig. 1c, Extended  Data Fig. 1e ). In addition, the percentage of cells undergoing apoptosis increased upon CDK12 loss (Fig. 1d, Extended Data Fig. 1f ). Failure to repair DNA damage during S-phase causes replication fork stalling and impaired DNA replication 15 , which is consistent with the decreased nucleotide incorporation during S-phase observed upon CDK12 depletion. Persistent DNA damage forces mES cells to differentiate or initiate apoptosis 16, 17 . The accumulation of cells in G1 after CDK12 loss is consistent with differentiating cells that have longer G1 phases and competent G1/S checkpoints 18 , and the increase in apoptosis is consistent with programmed cell death in response to unrepaired DNA damage. Indeed, withdrawal of Dox for 48 h resulted in the accumulation of DNA double-strand breaks (Fig. 1e, Extended Data Fig. 1g ). Furthermore, both total p53 and Ser15-phosphorylated (activated) p53 19 were upregulated upon CDK12 loss (Fig. 1f , Extended Data Fig. 1h ). Thus, CDK12 ablation results in phenotypes consistent with defective HR repair in mES cells.
To address the molecular consequences of CDK12 loss, we sequenced RNA after 24 and 48 h of CDK12 depletion. One hundred and forty genes (after 24 h) and 814 genes (after 48 h) showed significant changes in total gene expression (posterior probability of differential expression (PPDE) > 0.95) (Extended Data Fig. 2a, Supplementary Table 1 ). Corroborating the p53 activation observed upon CDK12 loss, approximately 33% of these genes were validated p53 targets that changed in the expected direction 20 (Extended Data Fig. 2b ). Consistent with induction of mES cell differentiation by p53 activation, there was also an enrichment of genes (12%) harbouring bivalent chromatin modifications (trimethylation of lysine 4 or lysine 27 on histone H3 (H3K4me3 and H3K27me3, respectively)), a marker of early differentiation genes, at their promoters 21 . These two gene signatures accounted for approximately 70% of the genes whose expression increased and 20% of the genes whose expression decreased upon CDK12 depletion. When we excluded these genes as likely secondary effects, we found that CDK12 depletion after 48 h modestly affected the total expression of only 428 (3%) of expressed genes, and most of those genes showed decreased expression upon CDK12 loss (Extended Data Fig. 2b ).
In addition to gene expression changes at the total transcript level, alterations in isoform usage also affect functional gene output. Although CDK12 has been implicated in alternative splicing 22 , we observed few splicing changes (Extended Data Fig. 2c ). We next examined alternative cleavage and polyadenylation. In addition to the polyadenylation site located after the 3′-most exon of a gene (the distal polyadenylation site), intronic polyadenylation sites (IPAs) occur throughout introns. Usage of IPAs produces truncated mRNA isoforms that vary in coding potential, stability, translational efficiency, and localization 23, 24 . Using 3′-end sequencing data from mES cells 25 to define high-confidence IPA and distal isoforms genome-wide, we found that CDK12-depleted cells showed global increases in IPA events at the expense of distal sites (Fig. 2a, b) ; this finding was validated by isoform-specific quantitative PCR following reverse transcription (RT-qPCR; Extended Data Fig. 2d-g ). Among 33,115 IPAs identified in 13,594 expressed genes 25 , 2,009 individual IPA isoforms (about 6.4% of identified IPA isoforms) were significantly (P adj < 0.05) differentially expressed upon CDK12 loss (Extended Data Fig. 2h , Supplementary Tables 2, 3 ). The vast majority of these IPA isoforms (1,824, 91%) increased upon CDK12 depletion.
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To quantify the expression of isoforms that result from the use of distal polyadenylation sites, we measured the expression of the distal-most exon as normalized to the rest of the transcript (Fig. 2a) . In contrast to IPA isoforms, the majority (1,848, 75%) of significantly (P adj < 0.05) changing distal isoforms decreased upon CDK12 loss ( Table 4 ). In a subset of these genes (571), we could detect a corresponding, statistically significant increase in at least one IPA isoform (Extended Data Fig. 2i ). The majority (56%) of the remaining genes that showed a decrease in expression of the distal isoform contained at least one IPA that increased in usage, even though they did not reach statistical significance. Whereas individual IPAs may not reach statistical significance owing to the presence of multiple IPA events within the same gene, the decrease in distal polyadenylation site usage represents the cumulative loss from each upstream IPA. Therefore, we consider these 1,848 genes with significantly decreasing distal exons also to be altered by CDK12-dependent IPA usage.
An intron may contain multiple IPAs, and a gene may contain multiple introns with IPAs. Collapsing the data to single genes indicated that 2,948 genes (about 22% of expressed genes) had at least one significantly increasing IPA isoform, a significantly decreasing distal isoform, or both (Fig. 2c) . We focused on this set of genes for the later mechanistic studies; however, notably, for all genes with an IPA, as a population the IPA isoform usage increased and distal isoform usage decreased whether or not the individual sites reached statistical significance (Fig. 2d) . Therefore, we conclude that the primary role of CDK12 is to suppress IPAs genome-wide and to promote expression of distal (full-length) isoforms.
As cleavage and polyadenylation occur co-transcriptionally and CDK12 phosphorylates the RNA polymerase II C-terminal domain (RNAPII CTD), we investigated whether CDK12 depletion resulted in changes to RNAPII or its Ser2 phosphorylation (Ser2p) status that might explain the increased IPA site usage. Using chromatin immunoprecipitation sequencing (ChIP), we mapped RNAPII and Ser2p RNAPII density genome-wide using two independent antibodies per target in biological duplicate. ChIP profiles from the two independent antibodies were highly similar (Extended Data Fig. 3 ). Therefore, Olive tail moment: the product of the percentage of total DNA in the tail and the distance between the intensity-weighted centroids of the comet head and tail. Box plots: median value with 25th and 75th quartiles, whiskers show minimum to maximum. P value based on one-sided MannWhitney U test. f, Immunoblot of total and Ser15 phosphorylated (Ser15p) p53 upon CDK12 loss.
Letter reSeArCH the data from both antibodies and biological replicates were aggregated throughout the metagene analyses (Extended Data Fig. 4a ). Furthermore, we developed a statistical framework (Extended Data Fig. 4b-d ) for reliably measuring differences in ChIP read density.
To analyse the effects on RNAPII elongation, we plotted metagene profiles of RNAPII density from the transcriptional start site (TSS) to the distal polyadenylation site (Distal polyA) (Fig. 3a) . Because RNAPII density correlates with gene expression levels and correlates inversely with gene length, we removed the shortest and longest length quartiles and focused on the middle two quartiles of genes (Extended Data  Fig. 5a, b) . Loss of CDK12 resulted in decreased RNAPII density at the 5′ ends of genes, transitioning to increased RNAPII density towards the 3′ ends (Fig. 3b, Extended Data Fig. 5b, c) . This pattern was not specific to genes with statistically significant CDK12-sensitive IPA or distal polyA isoforms and was observed in length-and expression-matched control gene sets (Extended Data Fig. 6 ).
To determine whether decreased RNAPII density at the 5′ ends of genes could be due to a reduction in RNAPII entering elongation, we aligned metagene profiles on the first stable nucleosome downstream of the promoter, a barrier associated with RNAPII entering productive elongation 26 ( Fig. 3a) . Upon CDK12 loss, RNAPII density increased upstream and decreased downstream of the first stable nucleosome, accounting for the decrease in RNAPII density at the 5′ ends of genes and indicating that less RNAPII entered productive elongation in these cells than in CDK12-expressing cells (Fig. 3c, Extended Data Fig. 7) . Therefore, the increased RNAPII density towards the 3′ ends of genes is most parsimoniously explained by altered elongation dynamics that cause progressive RNAPII accumulation across gene bodies upon CDK12 depletion. Consistent with its role as a RNAPII Ser2 kinase, 
Ser2p RNAPII decreased across the entire gene body upon CDK12 loss (Fig. 3d, Extended Data Fig. 8 ). Therefore, our data suggest that CDK12-mediated phosphorylation of the RNAPII CTD is associated with a positive effect on transcription elongation dynamics across all or most genes. How this activity could alter IPA site usage is discussed in Extended Data Fig. 9 .
We investigated whether enhanced IPA usage upon CDK12 depletion could account for the functional loss of HR that has been previously reported and that is reflected in our phenotypic data. Indeed, there is an enrichment for the BRCAness genes among those genes that show statistically significant increases in IPA usage or decreases in distal polyadenylation usage upon CDK12 loss (13 genes out of 22 BRCAness genes
, Fishers exact test). Furthermore, the distal polyadenylation isoforms of these 13 critical HR genes are more profoundly decreased as a group by CDK12 loss than the distal isoforms of other genes (Fig. 4a) . The enhanced sensitivity of HR genes to IPA activation is explained by two observations. First, the CDK12-sensitive HR genes are enriched in the frequency of IPAs per gene (Fig. 4b) . In genes with multiple IPAs, the negative effect of terminating at each individual IPA on the amount of full-length isoform is cumulative; consequently, we observed a strong correlation between the number of IPAs per gene and the effect of CDK12 depletion on the production of the full-length isoform for that gene (Fig. 4c) . Second, compared to expressed genes with the same number of IPAs, the HR genes showed increased sensitivity to CDK12 loss (Fig. 4a, c) . Our data suggest that the cumulative effect of multiple, high-sensitivity IPAs in HR genes accounts for the downregulation of their full-length isoforms. These isoform changes substantially decreased the expression of full-length protein (Fig. 4d, e) . As CDK12 activity maintains the full-length expression of more than half of the identified BRCAness genes, we propose 27, 28 and ovarian 29, 30 tumours. RNA sequencing data from the tumours of patients with ovarian serous adenocarcinoma 29 and prostate adenocarcinoma 27 showed that putative CDK12 LOF mutations, but not oncogenic mutations in other BRCAness genes, increased IPA usage within key BRCAness genes, including ATM, WRN, and FANCD2, compared to tumours that were wild type for CDK12 (Fig. 4f, g ; Extended Data Fig. 10a, b) . Notably, the tumour harbouring the CDK12(K975E) missense mutation, which was previously validated to have a minimal effect on CDK12 activity 5 , did not show increased ATM IPA expression (Fig. 4f) .
We treated prostate adenocarcinoma and ovarian carcinoma cell lines with the CDK12/CDK13 inhibitor THZ531 4 to validate the increased IPA usage observed in CDK12 mutant tumours; as expected, IPA usage increased (Extended Data Fig. 10c -e). These data suggest that the role of CDK12 in suppressing IPA usage is conserved in humans and that tumours harbouring CDK12 loss-of-function mutations upregulate IPAs, abrogating functional HR. Differential IPA usage may therefore serve as a biomarker for functional CDK12 (and thus HR) loss in tumours that harbour uncharacterized CDK12 mutations and could potentially be used to identify patients who would respond to targeted treatments against BRCAness phenotypes, such as PARP1 inhibitors.
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MEthodS
No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to outcome assessment except in the case of the comet assay results shown in Extended Data Fig. 1g , in which the researcher was blinded to the experimental condition of each sample during image acquisition. Cell culture, cell line generation and drug conditions. All cell lines were tested for mycoplasma contamination periodically, including immediately upon receipt and after generation of CRISPR-modified clonal cell lines via the MycoAlert Mycoplasma Testing Kit (Lonza). Results were always negative for mycoplasma contamination.
V6.5 (C57Bl/6-129) mES cells and derived cell lines were cultured on 0.2% gelatin-coated tissue culture plates in ES medium: Dulbecco's modified essential medium (Thermo Fisher) buffered with 10 mM HEPES (Thermo Fisher) and supplemented with 15% fetal bovine serum (Hyclone), 1,000 U/ml leukaemia inhibitory factor (Millipore), 1× non-essential amino acids (Thermo Fisher), 2 mM l-glutamine (Thermo Fisher), 0.11 mM β-mercaptoethanol (Sigma), 100 IU penicillin and 100 μg/ml streptomycin (Corning). Cdk12∆ clones were maintained in 1 μg/ml doxycycline (Dox) (Sigma) in ES medium (changed daily) to sustain complementing levels of CDK12. To investigate CDK12 loss, cells were washed at time zero with HBS and switched to ES medium without Dox.
Cdk12∆ clones were generated as follows (see Extended Data Fig. 1a) . A Cdk12-Flox clone was isolated using CRISPR-Cas9 genome editing technology 31 . Two sgRNA sequences targeting introns 3 and 4 of the endogenous Cdk12 locus were cloned into pX330 32 (a gift from F. Zhang, Addgene# 42230). Lipofectamine2000 (Thermo Fisher) was used to co-transfect wild-type V6.5 cells with the sgRNA plasmids, along with single-stranded oligodeoxynucleotides (ssODNs) from Integrated DNA Technologies (IDT) containing a LoxP sequence adjacent to an NcoI restriction site flanked on either side by 60-nucleotide homology arms complementary to intron 3 or intron 4 surrounding the sgRNA cut site, and the pLKO.1 plasmid harbouring a puromycin-resistance gene. sgRNA sequences and ssODN sequences are provided in Supplementary Table 5 . Cells were selected 24 h after transfection with 1 μg/ml puromycin (Sigma) for 48 h and single-cell cloned. Clones were screened for homozygous LoxP site insertion into both introns by PCR followed by NcoI digest. Positive clones were confirmed by Sanger sequencing. A Dox-inducible Cdk12 transgene was stably introduced into the Cdk12-Flox cell line using a piggybac retrotransposon system. N-terminal Flag-HA-tandem epitope-tagged Cdk12 (NM_001109626.1) was cloned from polyA-selected mouse cDNA into pCR8/GW/TOPO (Thermo Fisher) followed by transfer into the doxycycline-inducible piggybac expression vector, PBNeoTetO-Dest (a gift from A.W. Cheng), using standard TOPO and Gateway cloning kits (Thermo Fisher). This expression vector was cotransfected with pAC4 (constitutively expressing M2rtTA, the Dox-inducible transactivator, flanked by piggybac recombination sites, A.W. Cheng) and mPBase (piggybac transposase expression plasmid, A.W. Cheng) using Lipofectamine2000. 24 h after transfection, cells were selected with 150 μg/ml Hygromycin (Thermo Fisher) and 200 μg/ml G418 (Sigma) to select stable transformants. Subsequently, a constitutive Cre expression plasmid, pPGKCre-bpA (a gift from K. Rajewsky, Addgene plasmid # 11543), and a constitutive mCherry expression vector, pCAGGS-mCherry 33 were co-transfected using Lipofectamine2000 into the Cdk12 Flox cells with stably integrated doxycyclineinducible CDK12. 48 h after transfection, the cell population was single-cell FACS sorted for mCherry-positive cells. Beginning 4-6 h after Cre transfection, the cells were treated daily with 1 μg/ml Dox (Sigma)-supplemented ES medium to express rescuing levels of CDK12 protein. PCR was used to select clones harbouring homozygous deletions of exon 4 and exon 4 deletion was confirmed by Sanger sequencing across the locus. Several homozygous knockout clones were isolated and two clones were picked for subsequent analysis.
Endogenous N-terminal, V5-epitope tagged Atm, Brca2, and Fancd2 cell lines were made as follows. sgRNAs targeting genomic loci near the start codon of Atm, Brca2, and Fancd2 were cloned into pX330. gBlocks (IDT) containing a V5 epitope tag positioned in-frame, immediately adjacent to the start codon flanked by 64 to 354 nucleotides of homology were TOPO cloned and sequenced verified. sgRNA sequences and gblock sequences are provided in Supplementary Table 5 . For Atm, where homologous insertion of the V5 tag disrupted sgRNA/Cas9 cutting, we added a restriction enzyme site in frame to the end of the V5 tag to facilitate screening. For Fancd2 and Brca2, where homologous insertion of the V5 epitope tag did not inhibit sgRNA/Cas9 re-cleavage, we also engineered point mutations into the gBlock construct that would introduce a novel restriction enzyme site adjacent to the sgRNA PAM motif to disrupt sgRNA/Cas9 re-cutting and facilitate screening. Cdk12∆ cells were co-transfected with the appropriate sgRNA, TOPO-cloned gBlock, and pLKO.1 with blasticidin resistance. Cells were selected with 2 μg/ml blasticidin and single-cell cloned. Cells were screened by PCR followed by restriction enzyme digest. Heterozygous and homozygous insertions of the V5 tag were isolated and confirmed by Sanger sequencing across the locus. Two independent clones with homozygous or heterozygous insertions of the V5 tag were isolated and experiments were replicated in at least two independent clones. 22RV1 and PC-3 cells were from ATCC. OVCAR4 cells were from the Koch Institute's High Throughput Sciences Facility Cell Line Repository. All cell lines were authenticated by STR Profiling (ATCC) upon receipt. 22RV1 and OVCAR4 cells were grown in RPMI-1640 (Gibco) supplemented with 10% FBS (Tissue Culture Biologicals), 2 mM l-glutamine (Thermo), and 100 IU penicillin and 100 μg/ml streptomycin (Corning). PC-3 cells were grown in Ham's F-12K (Kaighn's) medium (Thermo Fisher) supplemented with 10% FBS (Tissue Culture Biologicals), 2 mM l-glutamine (Thermo), and 100 IU penicillin and 100 μg/ml streptomycin (Corning). Cells were treated with indicated concentrations of THZ531 4 or equivalent volumes of DMSO (vehicle control) for 4 h before harvest. FACS assays. FACS analyses were performed using BD FACS machines: FACS Celesta, LSRII, FACS Canto II, FACS LSR Fortessa, and FACS Aria IIIu. Data were collected using FACS Diva Version 8.0.1 and data was analysed using FlowJo version 1.0.1. Growth curve analysis. 24 h before starting the time course, cells were plated at the same cell number in biological triplicate for each of the first three time points of the experiment (0, 24, and 48 h) in +Dox medium; additional cells were grown in parallel cultures for the later time points. After 24 h, we split these parallel cultures into biological triplicates per condition for the final three time points of the experiment (48, 72 , and 96 h). Starting at time 0, cells received daily media changes with +Dox or −Dox medium as appropriate. At each time point, triplicate cell cultures were washed with HBS and harvested by trypsinization. Each biological replicate was resuspended in 450 μl of ES medium followed by addition of 1 μl of 50 μM calcein-AM in DMSO and 2 μl of 2 mM ethidium homodimer-1 (Thermo Fisher). Samples were incubated for 15-20 min at room temperature protected from light. After staining, 50 μl of CountBright Absolute Counting Beads (Thermo Fisher) was added to each sample. Samples were analysed by flow cytometry such that at least ~5,000 CountBright Absolute Counting Beads (~100 μl) were recorded per sample, during which samples were vortexed every minute to prevent counting beads from settling out of solution. The number of live cells per replicate was quantified in each sample by counting the number of live (Calcein-AM positive and Ethidium Homodimer-1 negative) cells and comparing it to the number of CountBright Absolute Counting Beads (with known concentration). An example of the flow cytometry gating strategy used is shown in Supplementary Fig. 1 . To calculate the fold change in live cells over the previous 24 h, the number of live cells in each biological replicate at each time point was compared to the average of the live cells in the three biological replicates at the previous time point to give the ratio of live cells every 24 h. Cell cycle profiling. Cells were plated at approximately equal cell densities 24 h before profiling, such that cells were 50-80% confluent at the time of harvest. Cells were pulsed with 10 μM 5-ethynl-2′-deoxyuridine (EdU) for 1 h under standard growth conditions, then harvested by trypsinization. Collected cell pellets were fixed, permeabilized, and stained for EdU incorporation with Alexa Fluor 647 using Click-iT EdU Flow Cytometry Assay Kit (Thermo Fisher) according to the manufacturer's instructions. After EdU staining, cells were resuspended in 1× Click-iT saponin-based permeabilization and wash reagent (Thermo Fisher) with 50 μg/ml propidium iodide to label total DNA content and 100 μg/ml RNase A. Cells were incubated at room temperature in the dark for 30 min, and at least 50,000 cells (Fig. 1c) and 20,000 cells (Extended Data Fig. 1e ) gated on P3 (see gating strategy in Supplementary Fig. 1 ) were analysed by flow cytometry for EdU content (AlexaFluor 647) and total DNA content (propidium iodide). An example of the flow cytometry gating strategy used is shown in Supplementary Fig. 1 . Apoptosis. Cells were plated at approximately equal cell densities at least 24 h before harvest. Cells were harvested by trypsinization. The growth medium and HBS wash before trypsinization were collected and centrifuged with the trypsinized cell population to collect any apoptosing cells with decreased adherence to the plate. Cell pellets were washed twice with cold PBS. Cells were fixed, permeabilized, and stained for cleaved caspase-3 (apoptosis) using the FITC Active Caspase-3 Apoptosis Kit (BD Pharmingen) and the recommended protocol. At least 50,000 stained cells (gated on P3, see gating strategy in Supplementary Fig. 1 ) were analysed by FACS. An example of the flow cytometry gating strategy used is shown in Supplementary Fig. 1 . Neutral comet assay. Assessment of DNA damage and double strand break formation in cells was performed using the single cell gel electrophoresis assay, CometAssay (Trevigen). Cells were harvested and resuspended in low-melting point agarose, plated onto provided glass slides, lysed, and subjected to electrophoresis in neutral electrophoresis buffer (100 mM Tris, 300 mM sodium acetate, pH 9.0). Slides were processed according to manufacturer's instructions and stained with SYBR Gold. After staining, coverslips were mounted onto slides with approximately 1 drop of ProLong Gold (Thermo Fisher) and cured overnight at room temperature protected from light. DNA tails were visualized using a Nikon
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Eclipse 80i fluorescence microscope and quantified using ImageJ software with the OpenComet plugin (http://www.opencomet.org) 34 . Western blotting. Whole-cell extract was harvested from cells by washing the cells in cold phosphate-buffered saline (PBS) and lysing in RIPA (10mM Tris pH7.4, 150mM NaCl, 1% TritonX-100, 0.1% SDS, 0.5% sodium deoxycholate, and 1 mM EDTA) supplemented with 1× cOmplete, EDTA-free Protease Inhibitors (Roche), 2 μl/ml benzonase nuclease (Sigma), and if needed, 1× Halt Phosphatase Inhibitor Cocktail (Thermo Fisher). Lysates were incubated on ice for at least 30 min, centrifuged for 10 min at 4 °C and max speed, and the cleared lysate was quantified using a standard BCA assay (Thermo Fisher). Lysates were normalized for equivalent total protein in 1× loading dye (62.5 mM Tris pH 6.8, 5% glycerol, 2% SDS, 16.67% BME, and 0.083% bromophenol blue) or 1× NuPAGE LDS Sample Buffer (Thermo Fisher) with 1× NuPAGE Reducing Agent (Thermo Fisher). Normalized lysates were boiled for 5 min or incubated at 70 °C for 10 min and run on one of the following types of precast gels: NuPAGE 4-12% Bis-Tris gels (Thermo Fisher), NuPAGE 3-8% Tris-Acetate Protein gels (Thermo Fisher), Novex 4-20% Tris Glycine gels (Thermo Fisher), Novex 10-20% Tris Glycine gels. Gels were transferred overnight (30 V) to PVDF in 10% methanol supplemented 1× NuPAGE Transfer Buffer (NuPAGE Bis-Tris Gels) for Bis-Tris and Tris-Acetate gels or 20% methanol-supplemented 1× Novex Tris-Glycine Transfer Buffer (Thermo Fisher) for Tris-Glycine gels. Primary antibodies used for blotting: anti-HA high affinity antibody (Roche 11867423001), Enolase I (CST 3810S), Vinculin (Sigma V9131), Hsp90 (BD 610418), p53 (1C12) (CST2524S), P-p53 Serine15 (CST 9284S), ATR (CST 13934S), FANCD2 (Abcam ab108928), and V5 (Life Technologies R96025). Secondary antibodies used all blots except the V5 epitope tag: ECL anti-rat IgG (GE Healthcare NA935V), ECL anti-mouse IgG (GE Healthcare NA931V), and ECL anti-rabbit IgG (GE Healthcare NA934V). For blots with the V5 epitope tag, we used the anti-mouse IgG, HRP-linked antibody (CST 7076S). Blots were exposed with Western Lightning Plus-ECL (Perkin Elmer) or SuperSignal West Dura Extended Duration Substrate (Thermo Fisher). RNA sequencing. Total RNA was harvested using Trizol Reagent (Thermo Fisher) from two independent Cdk12Δ clones each in biological duplicate from cells maintained in Dox (+Dox) or withdrawn from Dox for 24 h (−Dox 24 h) or 48 h (−Dox 48 h). In parallel, total RNA was harvested from Cdk12 floxed cells (without integrated Dox-inducible transgene) that had been pre-treated with 1 μg/ml Dox daily for 17 days and subjected to the same Dox conditions (+Dox, −Dox 24 h, −Dox 48 h) in biological duplicate to serve as a control for gene expression effects of long-term Dox treatment followed by short-term withdrawal. RNA was extracted following the standard Trizol protocol and subsequently DNase treated with Turbo DNase (Thermo Fisher) under standard reaction conditions. RNA quality was assessed by Agilent 2100 Bioanalyzer and only samples with a RIN value ≥ 9 were used for library preparation and sequencing. PolyA-selected libraries were made from 1 μg total RNA input using the TruSeq Stranded mRNA Library Prep Kit (Illumina RS-122-2102) with multiplexing barcodes, following the standard protocol with the following specifications: (1) 5 min RNA fragmentation time, (2) Superscript III (Thermo Fisher) was used for reverse transcription, (3) 15 cycles of PCR were used during the library amplification step, and (4) AMPure beads (Beckman Coulter) were used to size select/purify the library after PCR amplification instead of gel size selection. The 18 libraries were pooled and sequenced on two lanes of an Illumina NextSeq500. RT-qPCR. For total RNA (THZ531 treatments of human cell lines): cells were harvested in Trizol (Thermo Fisher) following the manufacturer's instructions. Isolated RNA was DNase treated with Turbo DNase (Thermo Fisher) under standard reaction conditions. Subsequently, RNA was extracted with acid phenol:chloroform and ethanol precipitated. Reverse transcription was performed using SuperscriptIII (Thermo Fisher) with normalized total RNA input (4-5 μg per reaction) in a 20-μl reaction with 1 μl of 50 μM olido(dT) 20 primer and standard reaction conditions (50 °C, 1 h). Each cDNA reaction was treated with 5U RNase H at 37 °C for 20 min and subsequently diluted 1:10 in ddH 2 O. Real-time qRT-PCR was performed using Power SYBR Green (Thermo Fisher) with 1-4 μl 1:10 diluted cDNA (depending on the target) and 200 nM forward and reverse primer mix (500 nM for HPRT control primer pair) on an ABI 7500 Real-Time qPCR machine or an ABI StepOnePlus machine. Primers spanning the exon 3-exon 4 junction of HPRT were used as a control to compare samples using a standard ∆∆Ct calculation. See Supplementary  Table 6 for primer sequences.
For purified mRNA (qPCR from Cdk12Δ clones): total RNA was purified directly from cells using the RNeasy Plus kit (Qiagen) and following the manufacturer's instructions. Subsequently, mRNA was purified from total RNA using the Oligotex mRNA Mini kit (Qiagen). Reverse transcription was performed using SuperscriptIII (Thermo Fisher) with normalized quantities of mRNA input (200-250 ng per reaction) in a 20-μl reaction with 200 ng random hexamer primers and standard reaction conditions (50 °C, 1 h). Each cDNA reaction was treated with 5 U RNase H at 37 °C for 20 min and diluted 1:10 in ddH 2 O. Real-time qRT-PCR was performed using Power SYBR Green (Thermo Fisher) with 1-4 μl 1:10 diluted cDNA (depending on target) and 200 nM forward and reverse primers on an ABI 7500 Real-Time qPCR machine or an ABI StepOnePlus machine. Primers to Pgk1 were used as a control to compare samples using a ∆∆Ct calculation. See Supplementary Table 6 for primer sequences. Chromatin immunoprecipitation sequencing. We modified a high-resolution, micrococcal nuclease (MNase) digestion-based ChIP methodology 35, 36 . We performed ChIP on Cdk12∆ cells under +Dox or -Dox 48 h conditions for total RNAPII density and Ser2p RNAPII density. Two independent antibodies were used for each antigen as follows: 8WG16 (Abcam ab817) and Rpb3 (Bethyl A303
Chromatin immunoprecipitation was performed as follows. In brief, 48 h before cells were harvested, 10 7 Cdk12Δ cells were plated in 15 cm dishes in either +Dox or -Dox ES medium. Cells were crosslinked directly in medium on the plate in 1% methanol-free formaldehyde (Thermo Fisher) for 10 min at room temperature. Crosslinking was quenched with 250 mM glycine. Cells were washed 3× in 10 ml chilled PBS and harvested by scraping. Cells were pelleted, washed in 10 ml chilled PBS, and pelleted again. PBS was aspirated off the cells and the pellets were flash frozen in liquid nitrogen and stored at −80 °C. Pellets were thawed on ice and resuspended in 0.9 ml of ChIP lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCL pH 7.5) supplemented with 1× cOmplete Protease Inhibitors (Roche) and 1× Halt Phosphatase Inhibitors (Thermo Fisher) and lysed for 10 min at room temperature. Pellets were diluted in 8.1 ml of ChIP Dilution Buffer (1% TritonX-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl pH 7.5) supplemented with 1× cOmplete Protease Inhibitors (Roche) and 1× Halt Phosphatase Inhibitors (Thermo Fisher) and 3 mM CaCl 2 . Each tube was pre-warmed at 37 °C for 2 min. Twelve units of micrococcal nuclease (MNase, Sigma) were added per tube and samples were digested for 30 min at 37 °C with rotation. The digestion reaction was quenched by the addition of 180 μl 500 mM EDTA and 360 μl 500 mM EGTA per tube. Samples were sonicated in 15-ml polystyrene tubes in a BioRupter (Diagenode) for 20 cycles on high (1 cycle = 30 s on/30 s off). Samples were cleared by centrifugation (max speed, 4 °C, 10 min).
Soluble material was transferred to a new tube and each sample (one pellet) was split into four 1.8 ml parts. Lysate was incubated overnight at 4 °C with rotation with 10 μg or 10 μl of acites fluid of the following antibodies: total RNAPII (8WG16 and Rpb3), and RNAPII CTD Ser2p (H5 and 3E10). After the overnight incubation, the immunoprecipitates were incubated for 2 h at 4 °C as follows: the 8WG16 and Rpb3 immunoprecipitates were incubated with 100 μl of Protein G Dynabeads (Thermo Fisher). The H5 immunoprecipitates were incubated with 100 μl of Protein G Dynabeads pre-conjugated overnight with 20 μg goat anti-mouse IgM (Thermo Fisher 31172) in Bead Preparation Solution (9 ChIP Dilution Buffer: 1 ChIP Lysis Buffer). The 3E10 immunoprecipitate was incubated with 100 μl of Protein G Dynabeads pre-conjugated with 20 μg goat anti-rat IgG (Thermo Fisher 31226). Immunoprecipitates were washed as follows: 2 × 2 ml LB3 (20 mM TrisHCl pH 7.5, 150 mM NaCl, 2 mM EDTA, 0.1% SDS, 1% Triton X-100); 1 × 2 ml LB3+ (20 mM Tris-HCl pH 7.5, 500 mM NaCl, 2 mM EDTA, 0.1% SDS, 1% Triton X-100); 1 × 2 ml Lithium Chloride Buffer (10 mM Tris-HCl, pH 7.5, 250 mM LiCl, 1 mM EDTA, 1% NP-40), and 1 × 2 ml TE + 50 mM NaCl (10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 50 mM NaCl). After washing, beads were resuspended in 200 μl of extraction buffer (50 mM Tris pH 8, 10 mM EDTA, 5 mM EGTA, 1% SDS). For WCE control, 100 μl of soluble input material was added to 100 μl of extraction buffer. Samples were incubated overnight at 65 °C with 1,000 r.p.m. shaking to elute immunoprecipitates and reverse crosslinks. 200 μl of eluted samples was cleared of beads and added to 200 μl TE pH 8. Samples were digested with 0.2 mg/ml RNaseA for 1 h at 37 °C. 7 μl of CaCl 2 solution (10 mM Tris-HCl, pH 8 and 300 mM CaCl 2 ) and 4 μl of 20 mg/ml proteinase K were added to each sample and incubated for 1 h at 55 °C. Samples were extracted in 1 × phenol:chloroform followed by 1 × chloroform and precipitated overnight at −80 °C with a standard NaCl, ethanol, and glycogen DNA precipitation. Pellets were washed twice in 1 ml 70% ethanol, dried, and resuspended in 70 μl 0.1× TE pH 8.
All of the ChIP material (70 μl resuspended) or 200 ng of input material (WCE) was used to prepare libraries. Sample DNA was end-repaired for 30 min at 20 °C in a 100 μl reaction: 1× T4 DNA Ligase Buffer (New England Biolabs, NEB), 0.4 mM dNTPs (NEB), 15 U of T4 DNA Polymerase (NEB), 5 U of Klenow enzyme (NEB), 50 U of T4 PNK (NEB). Samples were purified by Invitrogen Purelink Kit (Thermo Fisher) following standard conditions and eluted in 33 μl. 32 μl of purified product was A-tailed for 37 °C for 30 min in a 50-μl reaction with 1× NEB Buffer 2, 2 uM Letter reSeArCH dATP (NEB), and 15 U of Klenow exo-(NEB). Samples were purified by Invitrogen Purelink Kit and eluted in 11 μl. Illumina genomic adapters were ligated onto 10 μl of the purified product for 15 min at 20 °C in the following 50-μl reaction with 1× Quick Ligase Buffer (NEB), 400 nM of Y-shaped Adaptor Oligo, and 5 μl of Quick Ligase. The reaction was cleaned up by double size selection with AMPure beads as described by the manufacturer with the initial size selection using a 0.9× AMPure ratio and keeping the supernatant (to select against large products: mononucleosomes and larger) followed by a 1.8× AMPure selection keeping the bead bound material (to select against adaptor dimers and free adapters). Note: when switching between first and second size selection, we used the following formula provided by the manufacturer to calculate the amount of additional beads to add: (second ratio − first ratio) × volume transferred. Illumina adaptor oligos were added to the size selected product in a 50 μl PCR reaction with 200 μM dNTPs (NEB), 1× High Fidelity Phusion Buffer (NEB), 1 μl Phusion Polymerase (NEB), 0.5 μM forward Illumina oligo adaptor, and 0. 5 with the parameters: STAR --runMode alignReads --runThreadN 2 --genomeDir UCSC_mm9 --twopassMode Basic --sjdbOverhang 74 --outSAMtype BAM SortedByCoordinate --outFilterMultimapNmax 20 --outFilterMismatchNmax 999 --outFilterMismatchNoverLmax 0.04 --alignIntronMin 70 --alignIntronMax 500000 --alignMatesGapMax 500000 --alignSJoverhangMin 8 --alignSJDBoverhangMin 1 --outSAMstrandField intronMotif --outFilterType BySJout Gene expression quantification. Gene-level quantification was performed using Rsem version 1.2.26 39 and EBSeq version 1.10.1 40 using the UCSC mm9 genome annotation with four independent replicates each (2× technical replicates of 2× independent clones) for CDK12-expressing and CDK12-depleted samples at 24 and 48 h post Dox-withdrawal. Parameters:
rsem-calculate-expression --forward-prob 0.5 --output-genome-bam -p 2 --paired-end UCSC_mm9
Rsem analysis was followed by read-count matrix assembly and standard EBSeq differential expression analysis.
Gene-level and quantification was also performed using DESeq 41 to obtain independent validation as well as to derive an adjusted p value for use in gene expression volcano plots. Gene expression differences at the total gene level were considered significant if the PPDE as determined by EBSeq >0.95. Genes that exhibited statistically significant changes in response to doxycycline alone were excluded from the set of CDK12-affected genes. Gene expression data are provided in Supplementary Table 1 . Annotation of p53-target genes and bivalent promoters. p53 target genes were derived from previously published data 20 . In order to be considered a direct p53 transcriptional target gene, the gene was required to have a p53 ChIP peak within ~5.5 kb upstream and 2.5 kb downstream of the TSS, and exhibit a p53-dependent transcriptional response to DNA damage induced by adriamycin (doxorubicin) dosing in mouse ES cells. The directionality of transcriptional responses was determined by microarray-assayed gene expression changes.
Classification of bivalent-promoter genes was based on previously published data 21 . Genome-wide ChIP experiments were used as the basis for classifying genes based on histone modifications within the promoter region. Genes with H3K4-trimethylation overlapping H3K27-trimethylation in mouse ES cells were considered to belong to the bivalent class. Determination and quantification of alternative splicing events. Mapped splice junctions detected in all samples were combined and processed using custom Python scripts to filter out junctions representing < ~1% of transcripts. Alternative and constitutive intron classifications were performed using custom Python scripts, and are agnostic with regard to existing annotations other than known gene boundaries. If no overlapping introns exist for a given intron, it is assigned to the constitutive class. The subgroups containing overlapping introns are assigned a splicing classification if the start and end coordinates of all of the constituent introns fall into a pattern representing a known splice type (cassette, mutually exclusive, alternative 5′ splice site, alternative 3′ splice site).
To quantify differences in alternative splicing events between CDK12-expressing and CDK12-depleted cells, splicing events determined from mapped junctions as described above were converted into event-specific gff3 annotation files compatible with MISO 42 . We then performed two separate MISO analyses (one for each clone, comparing CDK12-expressing versus CDK12-depleted samples) per alternative splicing type. To be considered significant, splicing events in both independent clones were required to change in per cent-spliced in (delta-PSI) in the same direction, both with a Bayes factor of ≥ 5. Annotation of IPA sites. We used previously published 3′ end sequencing data 25 to identify genome-wide polyadenylation sites in the same strain of mouse ES cells used to generate the Cdk12Δ lines. These data were generated from poly(A)-selected RNA that was oligo-dT primed and reverse transcribed. cDNAs were circularized, PCR amplified, and sequenced. After mapping, the reads were filtered to remove genomically encoded poly(A) tracts and polyadenylation sites associated with B2-SINE retrotransposons. Putative cleavage sites were then required to have one of 36 strong, polyadenylation signal sequences within 40 nucleotides upstream. In the data analysis performed here, we first combined all cleavage sites from both control and U1-snRNA antisense morpholino oligonucleotide treated cells (two replicates each) and cleavage sites within 40 nucleotides of contiguous sequence were combined into the same cluster. Clusters were required to contain a minimum of 20 reads to be included in the analysis. Putative IPAs that overlapped an alternative 5′ splice site extending into the intron (as identified in our RNA sequencing data; see 'Determination and quantification of alternative splicing events' above) were excluded from the analysis. The genomic coordinates of these clusters are provided in Supplementary Table 2 . Genome-wide IPA transcript annotation and quantification. We used custom Python scripts to derive a transcriptome annotation based on Mm9 (Mus_mus-culus_NCBI_build37.1) gene start and end boundaries, the location of polyadenylation sites as determined by 3′ end sequencing (described above), and the genomic locations of all mapped splice junctions from the RNA-seq data. Annotation of the distal polyadenylation site isoform for each gene was based on the consensus isoform, that is, the junctions defining each exon are the most frequently used junction detected among all of the combined samples. Each IPA site within a gene was then assigned to an additional transcript based on the consensus isoform but terminating at the IPA cleavage site. These gene annotations were then converted to DEXseq exon parts using DEXseq-associated script dexseq_prepare_annotation. py and the reads mapping to each exon part in each sample were counted using dexseq_count.py. Using the counts matrix thus derived for all biological replicates in each condition, DEXseq was used to identify changes in the relative abundance of each exon part as normalized to all exon parts within the gene, including those representing the IPAs and distal polyadenylation site isoform 3′ terminal exon. This gave a log 2 -fold change and FDR adjusted P value for each exon part as it differed between the CDK12-expressing and CDK12-depleted samples. IPA sites or distal polyadenylation site isoform 3′ terminal exons whose exon part exhibited an adjusted P value <0.05 were considered statistically significant. Significantly changing IPA sites and distal polyadenylation site isoform 3′ terminal exons are listed in Supplementary Tables 3 and 4 , respectively. Determination of first stable nucleosome dyad positions. Genomic coordinates of nucleosome dyads in mES cells were download from previously published data 43 . To identify regions with stable nucleosomes, five different mES cell MNase-seq data sets were analysed with NucTools 44 . Stable nucleosome regions were determined using stable_nucs_replicates.pl with a sliding window of 50 bases and a relative error based on five replicates <0.5. The NucTools-defined stable region dyad downstream and most proximal to the transcription start site was regarded as the +1 dyad (first stable nucleosome). ChIP sequencing analysis. Custom Python and R scripts were used to calculate normalized read densities of ChIP data, bin for metagene analysis, and perform statistical tests. In brief, genomic coordinates for full genes or TSS-flanking regions for specific gene sets were first compiled. Mapped reads from ChIP data sets were counted within the specified regions using the Bedtools coverageBed tool 45 , combining both replicates of both antibodies for the ChIP under analysis. Each gene was divided into 100 equal-length bins and the total read counts per nucleotide for each gene within each bin were summed. Summed read counts were normalized by total mapped reads for the sample under consideration and the average of these count values across all genes was plotted as the normalized read density for that bin. Bin-wise P values were obtained using a one-sided Kolmogorov-Smirnov test comparing the distributions of normalized reads across all genes in the group between CDK12
+ and CDK12 − samples (see Extended Data Fig. 4) . Determination of Cdk12 sensitivity index. In order to determine the cumulative effect of IPA site usage on full-length gene expression, the log 2 -fold change between CDK12-depleted and CDK12-expressing samples in the ratios of the custom annotated first and last (distal polyA isoform) exons of each gene was calculated. We refer to this change in ratio as the CDK12 sensitivity index. The index for each gene was plotted as part of a distribution containing all other genes sharing the same total number of detected IPA sites as determined by the IPA annotation (see above). Identification and quantification of IPA sites in TCGA tumour samples. Patient samples from the prostate adenocarcinoma 27 and ovarian serous cystadenocarcinoma 29 TCGA cohorts were assessed for the presence of missense or truncating point mutations as well as copy-number variations (amplifications or deletions) in
CDK12 and BRCAness genes using cBioPortal (http://www.cbioportal.org/) 46, 47 . Additionally, normalized CDK12 mRNA expression levels were considered. We included all tumours from these cohorts in our analysis that were predicted to have CDK12 loss-of-function (LOF) mutation(s) as annotated in cBioPortal. We considered tumour genotypes to be likely CDK12 LOF mutations if they carried at least one truncating or missense putative driver mutation or if the copy number analysis classified the tumour as carrying a deep deletion (indicating a likely homozygous deletion across the locus) and if the mRNA expression levels of CDK12 were significantly downregulated compared to the mean expression in wild-type, diploid CDK12 tumours. We additionally included 4-5 shallow deletions from each tumour type that exhibited the lowest mRNA expression levels of CDK12, and one in-frame deletion mutant of unknown functional consequence. As an additional control for specificity, we included a single tumour carrying a CDK12(K975E) mutation that had been previously validated as a missense mutation with no LOF. The only CDK12 mutated tumours we excluded from consideration were three tumours in prostate carrying missense mutations of unknown consequence as we could not accurately classify them as wild-type or LOF.
A set of patients from the prostate and ovarian cohorts with wild-type, diploid CDK12 loci were selected along with one or two samples from each tumour type carrying an amplified locus. Among all such tumours, this control set was selected by ranking the tumours in order of normalized CDK12 mRNA expression and taking the subset with the highest expression (9 from each cohort). For the BRCAness control subset, we selected a set of tumours that carried only 'probably oncogenic' missense or truncating mutations and selected a set that contained all available BRCAness genes, as well as larger samples for genes that are more frequently mutated (for example, BRCA1/2 and CHEK2). These tumours were selected without considering CDK12 gene expression levels. Retrospectively, we also determined that two of the CDK12 wild-type diploid tumours carried putative deep deletions with mRNA loss in FANCA, CHEK1, and CHEK2 in one tumour and BRCA2 in the other; these tumours exhibited identical low IPA usage consistent with the other CDK12 wild-type tumours. Once the tumour sets had been selected based on these genomic characteristics, sequencing data from all of these tumours and only these tumours were downloaded and included in the quantifications performed as described below.
Aligned reads (STAR-mapped.bam files) covering relevant gene loci were downloaded from the Genomic Data Commons (https://gdc.cancer.gov/) using the bam-slicing tool. Reads were visually inspected to identify regions with clear IPA events that aligned with a canonical PAS motif. Regions spanning from the upstream 5′ splice site of the preceding exon to the PAS site were added to gtf annotations of the gene of interest, and DEXseq tools were used for annotating and counting reads mapping to each exon part as described above; these were used to generate a matrix of counts per exon part in each individual tumour sample. All exonic reads aligning within the gene were summed for each sample, and then read counts for each exon part were normalized to exon length and total exon counts in the gene for each sample to obtain a normalized IPA site usage metric for that sample. GraphPad PRISM 7 software was used to generate plots. Significance levels of the differences in IPA site usage between wild-type diploid versus the deletion and mutation group were determined using the Mann-Whitney U test (one-tailed). Statistics and reproducibility. All results with one representative example shown were repeated at least twice (n = 2 independent experiments) with each of those independent experiments from two independently derived clonal cell lines. Western blots for CDK12 expression: Cdk12Δ clone 36 (Fig. 1a ) n = 4 independent experiments and Cdk12Δ clone 28 (Extended Data Fig. 1c ) n = 4 independent experiments. Cell cycle profiling: Cdk12Δ clone 36 (Fig. 1c ) n = 3 independent experiments and Cdk12Δ clone 28 (Extended Data Fig. 1e ) n = 2 independent experiments. Cleaved Caspase 3 Apoptosis Staining: Cdk12Δ clone 36 (Fig. 1d ) n = 2 independent experiments and Cdk12Δ clone 28 (Extended Data Fig. 1f ) n = 2 independent experiments. Comet Assays: Cdk12Δ clone 36 (Fig. 1e ) n = 1 independent experiment and Cdk12Δ clone 28 (Extended Data Fig. 1g ) n = 1 independent experiment. Western blots for p53 and Ser15 phosphorylated p53: Cdk12Δ clone 36 (Fig. 1f ) n = 2 independent experiments and Cdk12Δ clone 28 (Extended Data Fig. 1h ) n = 1 independent experiment. Cdk12Δ genotyping gel (Extended Data Fig. 1b ) n = 2 independent experiments and PCR products were sequenced verified by Sanger sequencing. Endogenous ATR and FANCD2 expression upon CDK12 loss (Fig. 4d) were repeated in n = 2 independent experiments. All V5-epitope tagged western blots (Fig. 4e) were repeated in two independently derived homozygously or heterzygously V5-epitope, endogenously tagged clones. V5-ATM western blot (Fig. 4e) : clone 1 (n = 1) and clone 7 (n = 2). V5-BRCA2 (Fig. 4e) : clone 14 (n = 2) and clone 15 (n = 2). FANCD2 (Fig. 4e) : clone 5 (n = 3) and clone 35 (n = 3). Western blots from human cell lines treated with THZ531 (Extended Data Fig. 10c) were performed in n = 1 independent experiments to establish the concentration at which 22RV1, PC-3, and OVCAR4 cells responded to THZ531 treatment. qRT-PCR experiments based on these treatments (Extended Data Fig. 10d, e) were performed in n = 3 biological replicates. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper. Code availability. Custom scripts used for analysis are available upon request.
Data availability
Sequencing data have been deposited in the Gene Expression Omnibus under accession number GSE116017.
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Extended Data Fig. 3 | ChIP antibodies recognizing the same target protein exhibit strongly overlapping metagene patterns. Metagene profiles broken down by individual antibodies used. Blue lines: normalized read density for the specific ChIP antibody in n = 2 biological replicates. Orange lines: negative control (combined whole-cell extract and all antibody negative controls, n = 4 biological replicates). Black dashed lines:
fold-enrichment (specific ChIP/negative control). Shaded areas: −log 10 (bin-wise P values, Kolmogorov-Smirnov one-sided test) of the difference in read depth, with blue shading indicating that the plus CDK12 signal is significantly greater. The −log 10 of the P value is shown in the axis on the right, and the horizontal dashed line is P = 0.05. TSS, transcription start site. Distal polyA, distal polyadenylation site.
Extended Data Fig. 6 | RNAPII ChIP pattern is not specific to genes with CDK12-sensitive IPAs. a, Metagene profile of RNAPII density in a set of control genes length-matched to the set of genes with significantly changing IPA or distal isoforms. Top, all control genes. Bottom, shortest and longest quartiles removed (as in Fig. 3b) . b, Metagene profile of RNAPII density in a set of control genes length-matched to the set of genes with significantly changing IPA or distal isoforms, divided into length quartiles. c, Metagene profile of RNAPII density in a set of control genes expression-matched to the set of genes with significantly changing IPA or distal isoforms. d, Metagene profile of RNAPII density in a set of control genes expression-matched to the set of genes with significantly changing IPA or distal isoforms, divided into expression quartiles. a-d, Solid lines indicate normalized read density with (blue, n = 4 independent ChIPs) or without (red, n = 4 independent ChIPs) CDK12; shaded areas indicate −log 10 (bin-wise P value, Kolmogorov-Smirnov one-sided test) of the difference in read density (blue indicates that CDK12
+ signal is greater, pink indicates that CDK12
− signal is greater). Horizontal dashed line: P = 0.05.
Extended Data Fig. 8 | Ser2p is depleted by CDK12 loss and metagene patterns are influenced by gene expression and length. Left, metagene profiles of Ser2p RNAPII density in genes with a statistically significant (P adj < 0.05, FDR adjusted P value determined by the DEXSeq package in R) CDK12-sensitive IPA or terminal site divided into length-based quartiles. As in Fig. 3d , solid blue lines indicate average normalized read density in CDK12 + cells, red solid lines are the average normalized read density in CDK12-depleted samples. Light blue shading indicates that the plus CDK12 signal is significantly greater. n = 4 biological replicates per condition. Right, metagene profiles of Ser2p RNAPII density in genes with a statistically significant CDK12-sensitive IPA or terminal site divided into expression-based quartiles. n = 4 biological replicates per condition. The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
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Sample size
Sample sizes were not predetermined. Instead, sample sizes were selected based upon the availability of previously published data as outlined below.
TCGA cohorts of prostate adenocarcinoma and ovarian serous cystadenocarcinoma were assessed for the presence of missense or truncating point mutations as well as copy-number variations (amplifications or deletions) in CDK12 and BRCAness genes using cBioPortal (www.cbioportal.org). Additionally, normalized CDK12 mRNA expression levels were considered. We included all tumors from these cohorts in our analysis that were predicted to have CDK12 loss-of-function (LOF) mutation(s) as annotated in cBioPortal. We considered tumors to be likely CDK12 LOF if they carried at least one truncating or missense putative driver mutation or if the copy number analysis classified the tumor as carrying a deep deletion (indicating a likely homozygous deletion across the locus) and if the mRNA expression levels of CDK12 were significantly downregulated compared to the mean expression of WT, diploid CDK12 tumors. We additionally included 4-5 shallow deletions from each tumor type that exhibited the lowest mRNA expression levels of CDK12, and one in-frame deletion mutant of unknown functional consequence. As an additional control for specificity, we included a single tumor carrying a K975E mutation that had been previously validated as a missense mutation with no LOF. The only CDK12 mutated tumors we excluded from consideration were three tumors in prostate carrying missense mutations of unknown consequence as we could not accurately classify them as WT or LOF. 24 total CDK12 mutated tumors fit this criteria (n=12 prostate; n=12 ovarian).
A set of patients from the prostate and ovarian cohorts with wild-type, diploid CDK12 loci were selected along with one or two samples from each tumor type carrying an amplified locus (prostate n=1; ovarian n=2). Among all such tumors, this control set was selected by ranking the tumors in order of normalized CDK12 mRNA expression and taking the subset with the highest expression (9 from each cohort). For the BRCAness control subset (n=23; ovarian n=12 and prostate n=12), we selected a set of tumors that carried only "likely oncogenic" missense or truncating mutations and selected a set that contained all available BRCAness genes, as well as larger samples for genes that are more frequently mutated (e.g. BRCA1/2 and CHEK2). These tumors were selected without considering CDK12 gene expression levels. Retrospectively, we also determined that two of the CDK12 WT diploid tumors carried putative deep deletions with mRNA loss in FANCA, CHEK1, and CHEK2 in one tumor and BRCA2 in the other; these tumors exhibited identical low IPA usage consistent with the other CDK12 WT tumors. Once the tumor sets were selected based on these genomic characteristics, sequencing data from all of these tumors and only these tumors were downloaded and included in the quantifications performed.
Data exclusions Data exclusion criteria for the TCGA analysis ( Figure 4F ,G and Extended Data Fig. 10A ,B) was predetermined in that only tumors with RNA sequencing reads mapping to the genes of interest (ATM, FANCD2, or WRN) would be included in the isoform analysis. Two tumors with CDK12 mutations were excluded from the analysis of ATM IPA #1 and #2 because they showed no RNA sequencing reads mapping across the entire ATM locus (perhaps due to a deletion at the ATM locus).
Replication
All attempts at replication were successful. All results were replicated in two independent clonal cell lines (ie. two different Cdk12 knockout clones, two different V5 epitope-tagged clones, etc) in addition to replication within the same clonal cell line. For THZ531 treatments of human cancer cell lines (Extended Data Fig. 10C,D) we used three independent cancer cell lines, 2 cell lines derived from patients with prostate carcinoma (22RV1 and PC-3) and one cell line derived from an ovarian carcinoma patient (OVCAR4), to increase the robustness of our results. (1) 
Validation
All antibodies were validated by the manufacturer and used extensively throughout the literature. For all Western Blots where V5-epitope antibody was used, lysates from parental cells without introduction of the V5 epitope tag were run in parallel as a control for antibody specificity. All ChIP sequencing samples were performed alongside ChIP Western Blots (data not shown) to make sure that the antibody was appropriately recognizing the phosphorylation status of the CTD in our immunoprecipitations as predicted by mobility shifts.
Eukaryotic cell lines Policy information about cell lines
Cell line source(s)
Cdk12 knockout clones used in this study were derived from V6.5 (C57Bl/6-129) mouse embryonic stem cells, which were a gift from Rudolf Jaenisch's lab. 22RV1 and PC-3 cells were purchased directly from ATCC. OVCAR4 cells were a gift from Paula Hammond's lab and obtained from the Koch Institute's High Throughput Sciences Facility's Cell Line Repository.
Authentication
All human cell lines were authenticated upon arrival by STR profiling performed by ATCC using 17 short tandem repeat (STR) loci plus the gender determining locus, Amelogenin. Cells were considered authenticated if they were a 80% or greater allelic match to published STR profiles. The results are summarized below for each individual cell line. No commonly misidentified cells lines were used in this study.
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Data quality independent antibodies for each target and repeated the ChIP in biological duplicate for each one of these antibodies and conditions (16 libraries in total). Comparing metagene profiles of the average read densities of all ChIPs across biological replicates indicates that ChIP profiles from the two independent antibodies are highly reproducible and similar (Extended Data Fig. 3 ). We therefore aggregated data from both antibodies and both biological replicates throughout our metagene analyses in order to effectively incorporate four independent biological replicates per condition (Extended Data Fig. 4A ). Furthermore, we developed a robust statistical framework (Extended Data Fig. 4B-D) to measure the significance of the differences observed in ChIP signal in the presence and absence of Cdk12 in order to achieve a high level of confidence that we can reliably and reproducibly quantify even subtle differences in ChIP read density.
Software
BWA aligner version 0.7.12 was used to map ChIP sequencing reads. Metagene analysis was performed using custom python and R scripts. These scripts will be made available upon request.
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Methodology
Sample preparation
All Cdk12 knockout cells were derivatives of V6.5 (C57Bl/6-129) mouse embryonic stem cells as described in Extended Data Figure 1A and the Materials and Methods and were cultured according to the Materials and Methods.
Sample preparation was preformed as follows:
Growth Curve Analysis Each biological replicate was resuspended in 450uL of ES media followed by addition of 1uL of 50uM calcein-AM in DMSO and 2uL of 2mM ethidium homodimer-1 (Thermo Fisher). Samples were incubated for 15-20 minutes at room temperature protected from light. After staining, 50uL of CountBright Absolute Counting Beads (Thermo Fisher) was added to each sample. Samples were analyzed by flow cytometry such that at least ~5000 CountBright Absolute Counting Beads (~100uL of sample) were recorded per sample, during which samples were vortexed every minute to prevent counting beads from settling out of solution Cell Cycle Profiling Cells were plated at approximately equal cell density 24 hours prior to profiling, such that cells were 50-80% confluent at the time of harvest. Cells were pulsed with 10uM 5-ethynl-2'-deoxyuridine (EdU) for 1 hour under standard growth conditions, then harvested by trypsinization. Collected cell pellets were fixed, permeabilized, and stained for EdU incorporation with Alexa Fluor 647 using Click-iT EdU Flow Cytometry Assay Kit (Thermo Fisher) according to manufacturer's instructions. After EdU staining, cells were resuspended in 1x Click-iT saponin-based permeabilization and wash reagent (Thermo Fisher) with 50ug/mL propidium iodide to label total DNA content and 100ug/mL RNase A. Cells were incubated at room temperature in the dark for 30 minutes, and at least 50,000 cells (Fig. 1C) and 20,000 cells (Extended Data Fig. 1E ) gated on P3 (see gating strategy in Supplementary Data Figure 1 ) were analyzed by flow cytometry for EdU content (AlexaFluor 647) and total DNA content (propidium iodide). An example of the flow cytometry gating strategy used is shown in Supplementary Data Figure 1 .
Apoptosis
Cells were plated at approximately equal cell density at least 24 hours prior to harvest. Cells were harvested by trypsinization. The growth media and HBS wash prior to trypsinization were collected and centrifuged with the trypsinized cell population to collect any apoptosing cells with decreased adherence to the plate. Cell pellets were washed twice with cold PBS. Cells were fixed, permeabilized, and stained for cleaved Caspase-3 (apoptosis) using the FITC Active Caspase-3 Apoptosis Kit (BD Pharmingen) and the recommended protocol. At least 50,000 stained cells (gated on P3, see gating strategy in Supplementary Data Figure 1 ) were analyzed by FACS. An example of the flow cytometry gating strategy used is shown in Supplementary Data Cell population abundance Does not apply to any experiments in this study.
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Gating strategy
Representative gating strategy for all three FACS experiments is included in Supplementary Data 1.
For Growth Curve Analysis: To quantify CountBright Absolute Counting Beads (Thermo), we gated on BV421 positive (fluorophore that is not detected in cell population) and high side scatter. For stringency, we re-gated that population on BB515 positive and high side scatter, which produced almost identical (>99.9%) counts. To quantify live cells in the population, we initially gated single cells on SSC-Area versus FSC-Area followed by gating FSC-Height versus FSC-width to remove aggregates. We then gated live cells by plotting Ethidium Homodimer-1 versus Calcein-AM and selecting Calcein-AM positive and Ethidium Homodimer-1 negative cell populations. Single stained populations and unstained populations were run as controls. Cell only and bead only samples were also analyzed as controls.
For Cell Cycle Analysis: We first gated on single cells by gating on SSC-area versus FSC-area, followed by FSC-height versus FSC-width to remove aggregates, followed by SSC-height versus SSC-width to further remove aggregates. We then selected on the propidium iodide positive population to select stained, single cells. Following that, we plotted EdU incorporation as measured by AlexaFluor 647 (log scale) versus Propidium Iodide (linear scale) as measured on the PE-Texas Red detector and identified the three cycle phases as follows:
Cells that were EdU positive (S-phase) Cells that were EdU negative and 2n propidium iodide signal (G1 phase) Cells that were EdU negative and 4n propidium iodide signal (G2 phase). Single color and unstained controls were analyzed as controls to set the gates.
For Apoptosis Analysis:
We first gated on single cells by gating on SSC-area versus FSC-area, followed by FSC-height versus FSC-width to remove aggregates, followed by SSC-height versus SSC-width to further remove aggregates. We then plotted cells on Pacific Blue (negative control channel) versus FITC (cleaved caspase 3, test channel) to gate for cells that came off the diagonal indicating FITC signal above background, autofluorescence. Unstained cells were compared as a negative control.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
